What is the ticker symbol for Rapport Therapeutics?

Rapport Therapeutics trades under the ticker RAPP on NASDAQ.

What sector does Rapport Therapeutics operate in?

Rapport Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze RAPP in a portfolio?

PortView shows RAPP's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

Rapport Therapeutics (RAPP) Stock Analysis

NASDAQHealthcareBiotechnology

$47.83-1.51%

1-year price historyRange $14.36 – $52.50

52-week range$47.83

$14.11$52.93

What Rapport Therapeutics does

Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.

Key metrics

Market cap

$2.29B

P/E (TTM)

-15.73

EPS (TTM)

$-3.04

Beta

0.97

Dividend yield

0.00%

Revenue / share

$0.42

50-day avg

$43.80

200-day avg

$34.47

52-week high

$52.93

52-week low

$14.11

CEO

Abraham N. Ceesay

ETFs linked to RAPP

Broad-market and Healthcare sector ETFs an investor holding Rapport Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

SPY — SPDR S&P 500 ETF Trust VOO — Vanguard S&P 500 ETF QQQ — Invesco QQQ Trust VTI — Vanguard Total Stock Market ETF

PortView Portfolio Insights

PortView analyzes how RAPP fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze RAPP in PortView →

Similar companies

JNJ — Johnson &LLY — Eli Lilly A — Agilent Technologies ABBV — AbbVie Inc.ABT — Abbott Laboratories ALNY — Alnylam Pharmaceuticals

Frequently asked questions

What is the ticker symbol for Rapport Therapeutics?: Rapport Therapeutics trades under the ticker RAPP on NASDAQ.
Which exchange is RAPP listed on?: RAPP is listed on NASDAQ.
What sector does Rapport Therapeutics operate in?: Rapport Therapeutics is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze RAPP in a portfolio?: PortView shows RAPP's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.